PT  - JOURNAL ARTICLE
AU  - Eduardo Marquez-Martin
AU  - Francisco Ortega Ruiz
AU  - Elena Campano
AU  - Carmen De la Horra
AU  - Jose Manuel Varela
AU  - Enrique Calderón
TI  - Reduction in systemic inflammation by the PDE4 inhibitor roflumilast in patients with COPD
DP  - 2014 Sep 01
TA  - European Respiratory Journal
PG  - P926
VI  - 44
IP  - Suppl 58
4099  - http://erj.ersjournals.com/content/44/Suppl_58/P926.short
4100  - http://erj.ersjournals.com/content/44/Suppl_58/P926.full
SO  - Eur Respir J2014 Sep 01; 44
AB  - PURPOSE: Roflumilast is a targeted oral once-daily administered phosphodiesterase 4 (PDE4) inhibitor with clinical efficacy in chronic obstructive pulmonary disease (COPD) that has anti-inflammatory properties in both airways and lung parenchyma. However, if roflumilast is able to reduce systemic inflammation in COPD patients remains speculative.METHODS: In a post-marketing surveillance study, 21 men and one woman with severe COPD age 69.4 ± 7.7 years, received 500 mg roflumilast once daily for 12 weeks. Serum samples were collected before and after 12 weeks of treatment. Markers of inflammation were determined in serum samples using commercially available multiplex sandwich ELISA array (SearchLight, Billerica, MA, USA). Spirometry was performed at the start of roflumilast treatment and after 12 weeks.RESULTS: Roflumilast significantly reduced the serum levels of proinflammatory cytokine interleukin (IL)-8 (16.6 ± 10 pg/ml vs 12.8 ± 9.5 pg/ml, p = 0.02). Levels of soluble IL-2 (5.3 ± 9.5 pg/ml vs 7.5 ± 10.2 pg/ml, p= 0.36), IL-4 (0.07 ±0.1 pg/ml vs 0.06 ± 0.1 pg/ml, p= 0.49)), IL-10 (1.3 ± 1.6 pg/ml vs 1.04 ± 1 pg/ml, p= 0.2) and IL-13 (1.2 ± 2.3pg/ml vs 1 ± 2.3 pg/mg, p= 0.67) were not affected by treatment. FEV1 remained stable during roflumilast treatment (831.14 cc ± 239.6 vs 873.55 cc ± 237.8, p= 0.11).CONCLUSIONS: PDE4 inhibition by roflumilast treatment for 12 weeks reduced systemic inflammatory activity in patients with COPD.